The clinically most suitable method for minimal residual disease (MRD) detection in chronic lymphocytic leukemia is still controversial. We prospectively compared MRD assessment in 158 blood samples of 74 patients with CLL after stem cell transplantation (SCT) using four-color flow cytometry (MRD flow) in parallel with consensus IgH-PCR and ASO IgH real-time PCR (ASO IgH RQ-PCR). In 25 out of 106 samples (23.6%) with a polyclonal consensus IgH-PCR pattern, MRD flow still detected CLL cells, proving higher sensitivity of flow cytometry over PCR-genescanning with consensus IgH-primers. Of 92 samples, 14 (15.2%) analyzed in parallel by MRD flow and by ASO IgH RQ-PCR were negative by our flow cytometric assay but positive by PCR, thus demonstrating superior sensitivity of RQ-PCR with ASO primers. Quantitative MRD levels measured by both methods correlated well (r ¼ 0.93). MRD detection by flow and ASO IgH RQ-PCR were equally suitable to monitor MRD kinetics after allogeneic SCT, but the PCR method detected impending relapses after autologous SCT earlier. An analysis of factors that influence sensitivity and specificity of flow cytometry for MRD detection allowed to devise further improvements of this technique.
Introduction
During the last decade, it was demonstrated that advanced stage, distinct genomic aberrations, and an unmutated immunoglobulin heavy-chain (V H ) gene status characterize B-cell chronic lymphocytic leukemia (CLL) cases with high-risk features. [1] [2] [3] [4] [5] [6] At the same time with the advent of purine analogs, 7 monoclonal antibodies, [8] [9] [10] autologous 11, 12 and allogeneic SCT, [13] [14] [15] molecular remissions became an attainable therapeutic goal. These effective therapies and the known heterogeneity of the disease increased the importance of minimal residual disease (MRD) assessment as a surrogate marker for treatment efficiency in clinical studies. 10, 12, [14] [15] [16] [17] [18] Currently, immunoglobulin heavy-chain (IgH) PCR assays with allele-specific oligonucleotide (ASO) primers are accepted as the most sensitive technique for MRD detection in CLL. 14, 17, 19, 20 Real-time PCR using such ASO primers allows the quantitation of one CLL cell in 10 4 -10 5 cells. [21] [22] [23] A more rapid, but less sensitive and not quantitative method for MRD detection in CLL is PCR using consensus IgH-primers (consensus IgH-PCR). 12, 16, 18, 24, 25 This technique is reported to detect one monoclonal B-cell in 2 Â 10 1 -1 Â 10 3 benign leukocytes. 12, 16, 18, [26] [27] [28] Recently, four-color flow cytometry using the characteristic immunophenotype of CLL cells (MRD flow) has been introduced as a sensitive and quantitative tool for MRD detection in CLL, 29 thus improving known flow cytometric techniques. 18, 30, 31 Dilution studies predicted sensitivities of MRD flow of one CLL cell in 10 4 -10 5 normal leukocytes. 29, 32 Nevertheless, it is not known how results obtained using MRD flow, consensus IgH-PCR, and ASO IgH RQ-PCR relate to each other when tested simultaneously in the same samples. With increasing use of different methods for MRD detection in research and clinical practice, a direct comparison of these techniques in patients with low levels of residual CLL cells appeared mandatory. The aim of our study was, therefore, to evaluate sensitivity, specificity, and clinical utility of MRD flow in comparison to PCR techniques for MRD detection in CLL patients after autologous or allogeneic SCT.
Materials and methods

Patients and normal controls
Between July 9, 2002 and November 25, 2003 , MRD flow and PCR methods for MRD detection were applied in parallel to 158 peripheral blood samples from 57 patients (97 samples) after autologous SCT and from 17 patients (61 samples) after allogeneic SCT. Those patients from our three institutions were participating in ongoing prospective trials on nonmyeloablative allogeneic SCT (Dreger et . We included all samples with sufficient leukocytes to allow the simultaneous flow cytometric and molecular analysis. Eligibility for the trials and treatment protocols have been described in detail elsewhere. 11, 33 In brief, unmanipulated allogeneic peripheral blood stem cell grafts were transplanted after nonmyeloablative conditioning with fludarabine and cyclophosphamide. Graftversus-host disease prophylaxis consisted of cyclosporine A (tapered between day þ 60 and þ 100) and short-course methotrexate. For autologous SCT, immunoselected CD34 þ cells were transplanted after myeloablative therapy consisting of total body irradiation and high-dose cyclophosphamide. The protocols were approved by the responsible institutional review boards (Universities of Kiel and Ulm). All patients had CLL as confirmed by pathology and a typical CD19 þ CD5 þ CD23 þ immunophenotype at diagnosis. Patients suffering from Richter transformation were excluded from analysis. Judging from the number of previous therapies and the proportion of patients with unmutated V H gene status, the patients had to be considered as poor risk (Table 1) .
Peripheral blood samples from 23 healthy laboratory workers (median age: 33 years, range: 23-64 years) were collected after informed consent and analyzed by MRD flow in the same way as the CLL samples.
Flow cytometry
Samples were washed with phosphate-buffered saline (Sigma, Schnelldorf, Germany) containing 0.1% NaN 3 (Merck, Darmstadt, Germany) and 2% fetal calf serum (Sigma) and adjusted to 10 000 leukocytes/ml. 100 ml of this suspension were incubated with rabbit serum (Sigma) for 30 min and subsequently with a mixture of pretitered directly conjugated monoclonal antibodies (moabs) for 15 min. Moabs used were CD20 (clone L27, FITC, Becton Dickinson (BD), Heidelberg, Germany), CD5 (clone UCHT2, PE, BD), CD19 (clone SJ25C1, PerCP-Cy5.5, BD), and CD43 (clone L10, APC, Caltag, Hamburg, Germany). Samples were incubated with BD FACS Lysing Solution for 10 min, washed twice, and acquired using a BD FACSCalibur flow cytometer. In addition to daily calibrations using Calibrite beads (BD) and FACSComp v4.2 software (BD), isotype controls (incubated with four isotype-matched irrelevant moabs labeled with FITC, PE, PerCP-Cy5.5, and APC, all BD) were used to optimize light scatter, threshold, and amplification. Compensations were adjusted using four compensation controls (stained with single FITC, PE, PerCP-Cy5.5, and APC conjugated moabs). We acquired 8000 CD19 þ cells per sample or all leukocytes available, whatever came first (median 133 000 cells/sample, range 8739-366 936).
Data were analyzed using CellQuest Pro v4.0.1 software (BD). Our MRD flow assay utilized the immunophenotype
low for the identification of CLL cells. The gating strategy for identification of CLL cells ( Figure 1 ) was similar to the one described by Rawstron et al. 29 with the notable exception that we used CD43 þ instead of CD79b low as fourth criterion for CLL cells. In accordance with the literature on MRD in acute leukemias, [34] [35] [36] [37] we defined that at least 20 CLL cells forming a population in light scatter were required as evidence for MRD (absolute specificity threshold). In addition, a sample was judged as MRD positive only if the CLL cell number exceeded the relative specificity threshold. The relative specificity threshold was calculated as the cell number 2 standard deviations higher than the mean number of false positive cells in healthy controls (mean false positives þ 2 * s.d. false positives ) per 100 000 leukocytes acquired. MRD flow levels were obtained by dividing the number of CLL cells by the number of leukocytes. The MRD level was multiplied by the number of leukocytes/ml blood (assessed using a Sysmex KX 21 cell counter, Norderstedt, Germany) to obtain the number of CLL cells/ml blood.
Consensus IgH-PCR and genescanning
For consensus IgH-PCR, 500 ng DNA was amplified using FR1-IgH primer sets as described by the BIOMED-2 Concerted Action. 24 Briefly, genomic DNA was amplified by multiplex PCR using six family-specific FR1 and one FAM-labeled consensus J H primers. FAM-labeled PCR products were size separated on a high-resolution polyacrylamide gel and laserinduced fluorescence analyzed using an ABI 310 genetic analyzer (Applied Biosystems (ABI) Darmstadt, Germany) as described previously (genescanning). 24, 26 Follow-up samples were defined as monoclonal if peaks with identical lengths compared to pretherapeutic samples could be identified. In samples lacking amplifiable IgH-rearrangements, an albumin PCR was performed to check DNA quality.
IgH sequencing and mutational analysis
Clonal FR1-IgH PCR products were directly sequenced using an ABI 310 genetic analyzer as previously described in detail. 16 Obtained sequences were compared to published V H , D H , and J H germ-line sequences (DNAPLOT software and IMGT Database; http://imgt.cines.fr:8104; coordinator: Marie-Paul Lefranc, Montpellier, France) to identify somatic hypermutations and the individual clone-specific IgH complementarity determining region 3 (CDR3). A mutated V H gene was assumed if the difference to the nearest matching germ-line V H sequence exceeded 2%.
ASO IgH RQ-PCR
ASO primers were designed to match the hypervariable N-D-N region of the sequenced IgH-CDR3. ASO IgH RQ-PCR was performed with an ABI PRISM 7700 thermal cycler as described elsewhere. 22 Briefly, 500 ng of DNA was amplified using 300 nM of the consensus J H germ line and the individual ASO primers, 200 nM Taqman probe annealing to a downstream Table 1 Clinical details on patients from whom samples were included into the study family-specific J H region, and TaqMan Universal Mastermix (ABI). Reaction conditions were as follows: 501C 2 min, 951C 10 min followed by 45 cycles of 951C for 15 s and 59-641C (depending on ASO primer) for 60 s. Data were analyzed using the Sequence Detection Software v1.7 (ABI). Standards were generated from highly leukemic samples with known CLL cell content assessed by conventional flow cytometry. DNA of these samples was diluted into pooled polyclonal DNA from healthy individuals to final concentrations ranging from 1E-1 to 1E-5. The annealing temperatures for the ASO assays were adjusted to achieve highest specificity, as tested by amplifying pooled genomic DNA of healthy donors. Every quantitation was run with triplicate standards, duplicate follow-up samples, and two to five polyclonal negative controls. Sensitivity of an individual ASO IgH RQ-PCR assay was defined as the last dilution of the standard with a C T value more than one cycle lower than C T values found in one of the polyclonal DNA samples. Sensitivity was at least 1E-4, but in the majority of cases 4E-5-1E-5. To normalize MRD levels for differences in quality of DNA samples, the albumin gene was used as internal reference. Calculations of MRD levels were based on comparative C T analysis between follow-up samples and standards in ASO and albumin PCR. MRD values represent the proportion of the target copy number in the diagnostic sample that can be detected in 500 ng genomic DNA of the follow-up sample.
Statistical analysis
Two-tailed nonparametric Mann-Whitney and Wilcoxon matched pairs tests were used to compare unpaired and paired quantitative parameters, respectively. Qualitative parameters were compared using Fisher's exact test. Significance levels were set at 0.05. The nonparametric correlation coefficient r (Spearman) was calculated to compare MRD levels obtained by different methods. For MRD kinetics studies, a five-fold difference in MRD levels between the first and the last sample defined a significant change, allowing for the intra-assay variation of measurements. Calculations were carried out using GraphPad Prism software (release 3.02; San Diego, CA, USA).
Results
Comparison of MRD flow and consensus IgH-PCR
In all, 158 samples were tested in parallel by MRD flow and by consensus IgH-PCR. We obtained a monoclonal peak pattern in 43 
þ B-cell subpopulations accordingly. An MRD flow-positive event had to be contained in gates R2, R3, R4, and R5.
In 42 out of 43 samples (97.7%) that demonstrated monoclonality by consensus IgH-PCR, CLL cells were detected by MRD flow ( Table 2 ). The only sample with a monoclonal consensus IgH-PCR and a negative flow cytometric MRD result was from a patient 78 days after allogeneic SCT. In total, 0.69% of all leukocytes in this sample were B cells. On the other hand, in 25 out of 106 samples (23.6%) with polyclonal patterns, consensus IgH-PCR CLL cells were detectable by MRD flow. There was no flow cytometric evidence for CLL in two samples with an oligoclonal peak pattern by consensus IgH-PCR.
In seven out of total 158 samples (4.4%), neither polyclonal nor monoclonal signals were obtained by PCR. B cells were not detected by flow cytometry in four out of those seven samples. In the remaining three samples 3.0, 2.4, and 1.1% of leukocytes were B cells. Using MRD flow, 0.1% of total leukocytes in one sample were characterized as CLL cells, whereas CLL cells were not detected in the other two samples.
The median MRD levels in samples with monoclonal consensus IgH-PCR were significantly higher than in samples with polyclonal consensus IgH-PCR (Table 2 ). However, the highest MRD flow level measured simultaneously with a polyclonal consensus IgH-PCR was 5.1E-3 (21.9 CLL cells/ml), whereas the lowest MRD level determined simultaneously with a monoclonal consensus IgH-PCR was 2.2E-4 (1.4 CLL cells/ml). Therefore, in post-transplant CLL patients, MRD levels from 2.2E-4 to 5.1E-3 yield either monoclonal or polyclonal results by consensus IgH-PCR, whereas in samples with MRD levels higher than 5.1E-3 we always obtained a monoclonal pattern by consensus IgH-PCR.
Comparison of MRD flow and ASO IgH RQ-PCR
In 92 samples from 40 patients, we simultaneously analyzed MRD using ASO IgH RQ-PCR and flow cytometry (median samples per patient 2, range 1-11). MRD was detected in 61 samples by ASO IgH RQ-PCR, whereas 31 samples were MRD negative by this technique. Using MRD flow there was evidence for residual CLL cells in 47 samples. In all, 45 samples were tested MRD flow negative.
Of the 92 samples, 47 (51.1%) from 21 patients were positive by both techniques. 31 samples (33.7%) from 14 patients were concurrently tested negative using MRD flow and ASO IgH RQ-PCR. There was one patient with positive samples by both methods who later became MRD negative using both methods. Thus, the same qualitative MRD results were obtained in 78 of 92 samples tested (84.8%).
A total of 14 out of 92 samples (15.2%) from eight patients were negative by MRD flow but positive by ASO IgH RQ-PCR (median MRD level 5.2E-5, range 1.3E-5-1.6E-3). In two of those eight patients MRD flow and ASO IgH RQ-PCR concurrently demonstrated residual CLL cells at different time points during our study. There were no samples that yielded positive flow cytometric results but were tested MRD negative by ASO IgH RQ-PCR.
MRD levels measured by MRD flow and by ASO IgH RQ-PCR correlated well (r ¼ 0.93, Po0.0001, Figure 2 ). There was only one out of 47 concurrently positive samples (2.1%) in which MRD levels detected by both methods were more than 1 order of magnitude different from each other. A median MRD level of 3.2E-3 (range 2.2E-4-3.2E-1, corresponding to 0.4-7198 CLL cells/ml blood) was detected by MRD flow, whereas ASO IgH RQ-PCR detected in the same samples a median MRD level of 6.1E-3 (range 2.4E-5-6.7E-1, Po0.0001). In agreement with those data, we obtained the following equation by regression analysis: MRD flow ¼ 0.38 * MRD ASO IGH RQ-PCR þ 0.008. Thus, within the common sensitivity range of both techniques, MRD flow detected fewer CLL cells than RQ-PCR. 
Table 2
Comparison of consensus IgH-PCR and MRD flow (***Po0.0001) 
Specificity and sensitivity of MRD detection by flow cytometry
Sensitivity and specificity of our MRD flow assay was assessed by control experiments using blood samples from healthy donors and by comparison of flow cytometric MRD results with ASO IgH RQ-PCR as reference method.
To determine the relative specificity threshold of our MRD flow assay, the frequency of cells with CLL immunophenotypes in 23 healthy individuals was measured (Table 3) . A mean of 0.3 cells/ml blood with the typical CLL immunophenotype CD19 þ CD5 þ CD43 þ CD20 low were detected (median leukocytes analyzed: 619 000). This corresponded to a mean of 3.9 cells (range 1
þ . Specificity and sensitivity of different gating strategies for flow cytometric MRD detection compared to ASO IgH RQ-PCR were analyzed in 92 post-transplant CLL samples (Table 3) . 
Clinical utility of MRD flow after allogeneic and autologous SCT
The clinical utility of an assay for MRD detection strongly depends on its ability to monitor MRD kinetics to predict impending relapse and to document successful therapeutic interventions. We therefore compared MRD kinetics measured by MRD flow to time from allogeneic and autologous SCT, to MRD kinetics determined by ASO IgH RQ-PCR, and to V H mutation status. This analysis was restricted to 29 patients (67 samples) after autologous and 10 patients (51 samples) after allogeneic SCT with at least two sequential samples available spanning a time interval of more than 100 days.
In three out of 10 patients, after allogeneic SCT decreasing MRD levels were measured by MRD flow (Table 4) . Strikingly, these three CLL patients with reductions in MRD were monitored during the first 150 days after allogeneic SCT (Figure 3a) . From seven different patients samples were available for MRD flow during later follow-up after allogeneic SCT (range: 164-1445 days from SCT, median 710 days). CLL cells were not detected in six of those patients at any time point assessed. In one patient, we detected increasing MRD levels by MRD flow (Figure 3b) . The first available sample of day 858 after SCT was already positive by MRD flow (level 6.2E-3, 44 CLL Table 3 Comparison of gating strategies for CLL detection using MRD flow cells/ml). Subsequent samples showed steadily increasing MRD levels on days 1093 and 1204 (levels 3.2E-2 and 8.3E-2, 166 and 465 CLL cells/ml). On day 1235 after SCT, CLL cells were detectable by routine flow cytometry and the patient was treated with donor lymphocyte infusions. MRD kinetics were monitored by MRD flow in 29 patients after autologous SCT. In five patients, we measured increasing MRD levels. The first MRD flow positive sample in those patients contained CLL cells at a median level of 8.4E-4 (2.9 CLL cells/ml). In samples from further seven patients, low level MRD (median level 2.2E-3, median 2.8 CLL cells/ml) was detected without significant change over observation time. CLL cells were not detectable in 17 patients after autologous SCT by MRD flow. None of the 29 autologous SCT patients analyzed for MRD kinetics relapsed clinically. We conclude that MRD flow can detect residual CLL cells in a significant proportion (12/29, 41.3%) of patients after autologous SCT. In contrast to kinetics after allogeneic SCT, all patients with detectable CLL cells after autologous SCT showed stable or increasing, but never decreasing MRD flow levels during follow-up.
In 24 patients (nine allogeneic, 15 autologous SCT), the kinetics of MRD levels was assessed in parallel by ASO IgH RQ-PCR and by MRD flow. After allogeneic SCT, qualitatively identical kinetics by these methods was measured in every patient (Table 4 and Figure 3 ). After autologous SCT, both methods yielded identical results in 12 out of 15 patients. However, in one patient MRD flow detected a slightly lower increase in MRD level compared to ASO IgH RQ-PCR (4.1 vs 6.6-fold). A total of two patients after autologous SCT showed stable MRD by ASO IgH RQ-PCR (maximum levels: 4.3E-5 and 5.4E-5, respectively), but were tested negative by MRD flow.
We related mutational status of the V H gene to MRD kinetics assessed by flow cytometry. All 10 patients monitored for MRD kinetics after allogeneic SCT had an unmutated V H gene status. After autologous SCT, one out of five patients with increasing MRD and two out of seven patients with stable MRD, but eight out of 17 patients without detectable residual disease had a mutated V H gene status (20, 29 , and 47% respectively, ns). The time from transplantation to sample collection was comparable between those three groups (median 698, 994, and 784 days). The data suggest a correlation between mutated V H gene status and durable absence of MRD as assessed by flow cytometry after autologous SCT.
Discussion
The objective of this study was to evaluate recently introduced four-color MRD flow in comparison to two PCR techniques for MRD detection in clinical samples from CLL patients after SCT. This paper reports on the largest cohort of CLL patients simultaneously analyzed for MRD using four-color flow cytometry and consensus IgH-PCR. With 23.6% of samples MRD flow positive and simultaneously polyclonal in consensus IgH-PCR we extend the observation of Rawstron et al 29 that MRD flow is the more sensitive technique. The maximum sensitivity of our PCR assay for monoclonal CLL cells was 2.2E-4 (0.022% of all leukocytes), whereas others reported maximum sensitivities of 4E-3 29 and 1E-3. 18 Our consensus IgH-PCR is probably very sensitive because of the scarcity of polyclonal B cells in some samples and the use of genescanning as a sensitive detection method for clonality. 24 Consensus IgH-PCR yielded either polyclonal or monoclonal results simultaneously with MRD flow levels ranging from 2.2E-4 to 5.1E-3. The different sensitivity between samples likely results from different fragment size of the monoclonal PCR products and from different polyclonal background. Genescanning represents polyclonal B cells as multiple peaks resembling a Gaussian distribution of fluorescence intensity vs fragment size, whereas a monoclonal population is represented by a In 15 patients, MRD kinetics were not assessed using ASO IgH RQ-PCR.
Figure 3
Kinetics of MRD detection after SCT using MRD flow and ASO IgH RQ-PCR simultaneously. (a) Decreasing MRD levels after withdrawal of GvHD prophylaxis in a patient after allogeneic SCT. In the majority of patients, MRD becomes undetectable after day 150 using both methods. (b) Steadily increasing MRD levels in a patient after allogeneic SCT who eventually required donor lymphocyte infusions.
single peak of high fluorescence intensity. Monoclonal PCR products are therefore most easily distinguished from polyclonal background if their fragment size differs from the mean of that Gaussian distribution. Furthermore, the presence of polyclonal B cells limits the sensitivity of consensus IgH-PCR. 24 Therefore, in samples with a high polyclonal B cell background or with a certain length of the monoclonal PCR product consensus IgH-PCR is expected to be less sensitive. We conclude that the quantitative predictive value of monoclonality in consensus IgH-PCR is limited while a polyclonal PCR genescanning result predicts an MRD level of less than approximately 0.5% (5.1E-3) . However, the recurrence of monoclonality in a patient who was previously tested polyclonal predicts impending relapse. During follow-up, the length of the monoclonal PCR product remains the same and there are comparable numbers of polyclonal B cells in the sample.
Samples without detectable polyclonal or monoclonal signals in genescanning are rare (4.4%). We demonstrate herein that low B-cell content is a frequent reason for an unsuccessful consensus IgH-PCR explaining more than half of those cases. In addition, there are cases in which consensus IgH-PCR fails despite the presence of B cells, possibly due to inhibitors of PCR.
Our study for the first time directly compares ASO IgH RQ-PCR to an MRD flow assay in patients with CLL. In our series, there were no MRD flow positive samples with detectable residual CLL by RQ-PCR. However, 14/92 samples were positive by ASO IgH RQ-PCR, but simultaneously negative by our MRD flow assay. Thus, our data demonstrate higher sensitivity of ASO IgH RQ-PCR compared to our MRD flow assay in post-transplant CLL patients. This contradicts in vitro data that had predicted sensitivities of ASO IgH RQ-PCR [21] [22] [23] within the same order of magnitude as for MRD flow approaches (one CLL cell in 10 4 -10 5 normal cells). 18, 25, 29, 30 We therefore analyzed factors that influence specificity and sensitivity of MRD flow as the apparently less sensitive method.
Specificity of flow cytometry is partly ensured by analysis of cell populations. If the absolute number of cells required for a population (absolute specificity threshold) is too low, specificity decreases because cells from previous experiments, electronic noise, and impurities of the fluidics system are mistaken for residual CLL cells. 38 In accordance with reports on MRD flow for acute leukemias, we defined 20 events as absolute specificity threshold. [34] [35] [36] [37] A second prerequisite for specific MRD detection is that the number MRD-positive cells is higher than the expected number of false positive events per 100 000 leukocytes analyzed (relative specificity threshold). The relative specificity threshold is particularly dependent on debris and unspecific antibody binding. 38 It is influenced by conjugation, clone, and target of the moabs used, by lysing procedures, [39] [40] [41] by gating strategies, and by the immunophenotype of nonmalignant cells present in the sample. 42 From our analysis of 23 healthy donors, we calculated a relative specificity threshold of 9.7 false positive cells per 100 000 leukocytes measured. The relative specificity threshold would limit the sensitivity of our flow cytometric MRD assay at about 1E-4 (9.7/100 000), even if very high numbers of leukocytes were analyzed. However, in our study, there were no samples in which the sensitivity of MRD was limited by the relative specificity threshold (data not shown). Whenever a sample was tested negative by MRD flow, the number of CLL cells detected was lower than the absolute specificity threshold (20 events). We conclude that while our flow cytometric technique was sufficiently specific, the total number of events acquired restricted the maximum sensitivity of our MRD flow approach. A prerequisite for a more sensitive MRD flow assay is to measure more leukocytes. In addition, to obtain the same sensitivity like ASO IgH RQ-PCR (4E-5-1E-5 in most samples), it would probably be necessary to use a more specific immunophenotype for the immunological identification of CLL cells.
Therefore, the contribution of the novel criterion CD43 þ to sensitivity and specificity of our MRD flow assay was investigated. CD43 is homogenously expressed on CLL cells. [43] [44] [45] Moreover, in comparison to CD5, fewer benign B cells after SCT coexpress CD43 (data not shown). Owing to this relatively high specificity for CLL cells, CD43 appeared as a useful marker. We found that from all flow cytometric approaches tested, only the four-color immunophenotype CD19 þ CD5 þ CD43 þ CD20 low was 100% specific for CLL in comparison to ASO IgH RQ-PCR up to a maximum sensitivity of 2.2E-4. Surprisingly, in spite of the upregulation of CD5 on benign B cells after SCT (our unpublished data and demonstrated before 46, 47 þ CD5 þ CD20 low should be included in future attempts to increase sensitivity of MRD flow for CLL.
Apart from high sensitivity and specificity to qualitatively assess a sample as MRD positive or MRD negative, assays for MRD detection are required to yield statistically reliable quantitative MRD levels. It has been reported that MRD determinations by RQ-PCR at a level of 1E-4 resulted in a coefficient of variation (CV) of 32%. 21 For MRD flow (like for all rare cell measurements by flow cytometry 48 ), the CV is dependent on the absolute number of CLL cells acquired. Although we did not formally determine the retest reliability of our assay, at the absolute specificity threshold (20 CLL cells), a CV of about 23% is expected. In view of the expected considerable variability, the quantitation results obtained by MRD flow and by ASO IgH RQ-PCR correlated remarkably well (r ¼ 0.93, Po0.0001). We conclude that within the common sensitivity range both methods are equally suited to measure MRD in CLL patients. However, MRD flow consistently detected lower MRD levels than ASO IgH RQ-PCR. This might be explained by apoptotic CLL cells that escape flow cytometric light scatter criteria, while their DNA fragments can still serve as templates in RQ-PCR, as proposed by others. 34 In addition, subpopulations of residual CLL cells might not express the typical CD19 þ CD5 þ CD43 þ CD20 low immunophenotype. On the other hand, in relation to the initial samples, allele-specific sequences in follow-up samples might be less easily amplified by PCR.
Having assessed sensitivity, specificity, and accuracy of MRD flow and ASO IgH RQ-PCR, we investigated the clinical utility of both methods. Samples included in this study were from patients who participated in controlled clinical trials. Therefore, it was possible to relate post-transplant kinetics of MRD levels determined by MRD flow in our patients to published results from similar treatment protocols.
Our data on nonmyeloablative allogeneic SCT suggest that MRD flow reproducibly detects a decrease in residual CLL cells simultaneously with the reduction of immunosupression during the early post-transplant period (cyclosporine A was tapered between days þ 60 and þ 100). This observation agrees with the delayed clearance of CLL cells after allogeneic SCT reported before. [13] [14] [15] 18, 33 In general, MRD was not detectable during later follow-up, the only exception being a patient who eventually had to be retreated. In all patients after allogeneic SCT studied in parallel by MRD flow and by ASO IgH RQ-PCR, both methods showed the same MRD kinetics. Although the value of our observations is limited by low case numbers and short follow-up, both MRD flow and RQ-PCR appeared to be suited for guidance of immunomodulatory interventions during the early phase after SCT and before clinical relapse. Further studies are warranted to investigate what defines increasing MRD kinetics prior to relapse, since MRD-positive samples without clinical relapse have been reported. 25 After autologous SCT it is possible to measure clinically relevant MRD kinetics using flow cytometry. We identified a group of patients with increasing MRD levels by flow cytometry, while MRD in others remained stable during follow-up. Clinically important information was not lost compared to ASO IgH RQ-PCR in those cases, since both techniques yielded qualitatively identical results. Allowing for the short observation time, the kinetics measured by MRD flow are consistent with a steady, but differently fast increase in MRD levels in all MRDpositive patients after autologous SCT, as reported by our group using different techniques 16, 33 and by others. 25, 29 However, in a minority of patients (2/15, 13.3%) after autologous SCT, ASO IgH RQ-PCR detected recurrent low level CLL even in MRD flow-negative samples. These results are in accordance with the superior sensitivity of ASO IgH RQ-PCR compared to our MRD flow assay as demonstrated in this paper for the entire study group of post-transplant CLL patients.
We demonstrate in this paper a trend towards an increased proportion of patients with mutated V H region in the patients cohort that remain MRD flow negative following autologous SCT. This result is in agreement with our published observation that patients with unmutated V H region relapse earlier after autologous SCT than patients with mutated V H region 16 and supports the validity of the MRD kinetics determined using our MRD flow approach.
After allogeneic and autologous SCT for CLL, our MRD flow approach is a quantitative, sensitive, and specific method to monitor MRD in peripheral blood. ASO IgH RQ-PCR is more sensitive, but labor-intensive and costly. Its application after SCT for CLL could therefore be restricted to MRD flow-negative samples. However, it remains to be demonstrated in controlled clinical trials whether the earlier detection of an impending relapse after SCT using ASO IgH RQ-PCR is clinically advantageous.
